Clinical Trials in Optic Nerve Disease Treatment
Autor Jeffrey N. Weissen Limba Engleză Hardback – 9 iul 2024
Clinical Trials in Optic Nerve Disease Treatment is a valuable resource for ophthalmologists, optometrists, other physicians, and researchers.
Preț: 1048.48 lei
Preț vechi: 1103.67 lei
-5% Nou
Puncte Express: 1573
Preț estimativ în valută:
200.75€ • 209.04$ • 166.56£
200.75€ • 209.04$ • 166.56£
Carte tipărită la comandă
Livrare economică 10-15 februarie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783031588143
ISBN-10: 3031588142
Pagini: 420
Ilustrații: XII, 329 p.
Dimensiuni: 155 x 235 mm
Ediția:2024
Editura: Springer Nature Switzerland
Colecția Springer
Locul publicării:Cham, Switzerland
ISBN-10: 3031588142
Pagini: 420
Ilustrații: XII, 329 p.
Dimensiuni: 155 x 235 mm
Ediția:2024
Editura: Springer Nature Switzerland
Colecția Springer
Locul publicării:Cham, Switzerland
Cuprins
Part 1: Introduction.- Chapter 1. Introduction to Optic Nerve Disorders.- Part 2: Stem Cell Studies.- Chapter 2. Recruiting Trials in the Americas.- Chapter 3. Completed Trials.- Chapter 4. Terminated Trials.- Chapter 5. Withdrawn Trials.- Chapter 6. Unknown Status Trials.- Part 3: Gene Therapy.- Chapter 7. Recruiting Trials.- Chapter 8. Completed Trials.- Chapter 9. Not Yet Recruiting Trials.- Chapter 10. Active, Not Recruiting Trials.- Chapter 11. Unknown Trials.- Part 4: Other Treatment Studies.- Chapter 12. Recruiting Trials.- Chapter 13. Completed Trials.- Chapter 14. Terminated Trials.- Chapter 15. Unknown Status Trails.
Notă biografică
Jeffrey N. Weiss, M.D., is the former Chief of Retinal Surgery at the Joslin Diabetes Center in Boston, Faculty of Harvard Medical School, and Visiting Scientist at the Massachusetts Institute of Technology.
Dr. Weiss is the author of more than 100 publications, including 20 books, holds more than 20 U.S. and foreign patents and has been a Reviewer for multiple scholarly journals. He has served as a Visiting Professor, performed surgery, and lectured both nationally and internationally. Dr. Weiss is also the founder of two companies, Ocular Research Associates Inc., and Micron Ophthalmic, Inc., which have manufactured and sold Dr. Weiss’ inventions worldwide.
Dr. Weiss was the first to invent the equipment and develop the technique to safely perform retinal vessel cannulation. This surgery remains the only option for patients with severe stroke in the eye. He was also the first to report the use of hyperbaric oxygen treatment tosuccessfully treat dry age-related macular degeneration and longer standing central retinal artery occlusions.
Dr. Weiss performed the first retinal stem cell surgery in 2010, and is the Principal Investigator of The Stem Cell Ophthalmology Treatment Studies I/II, the largest retinal and optic nerve stem cell studies in the world, and The Neurologic Stem Cell Treatment Study. The studies are Institutional Review Board (IRB) approved, registered with NIH, and listed on ClinicalTrials.gov.
Dr. Weiss is the author of more than 100 publications, including 20 books, holds more than 20 U.S. and foreign patents and has been a Reviewer for multiple scholarly journals. He has served as a Visiting Professor, performed surgery, and lectured both nationally and internationally. Dr. Weiss is also the founder of two companies, Ocular Research Associates Inc., and Micron Ophthalmic, Inc., which have manufactured and sold Dr. Weiss’ inventions worldwide.
Dr. Weiss was the first to invent the equipment and develop the technique to safely perform retinal vessel cannulation. This surgery remains the only option for patients with severe stroke in the eye. He was also the first to report the use of hyperbaric oxygen treatment tosuccessfully treat dry age-related macular degeneration and longer standing central retinal artery occlusions.
Dr. Weiss performed the first retinal stem cell surgery in 2010, and is the Principal Investigator of The Stem Cell Ophthalmology Treatment Studies I/II, the largest retinal and optic nerve stem cell studies in the world, and The Neurologic Stem Cell Treatment Study. The studies are Institutional Review Board (IRB) approved, registered with NIH, and listed on ClinicalTrials.gov.
Textul de pe ultima copertă
This book is a compendium of the worldwide ocular stem cell, gene therapy, and other studies treating Optic Nerve Disease that are registered with Clinicaltrials.gov. The study and the Clinical Trial number is provided in order to make it easier for the reader to obtain further information. The book contains an introduction to Optic Nerve Disease as well as a summary of common optic nerve conditions.
Clinical Trials in Optic Nerve Disease Treatment is a valuable resource for ophthalmologists, optometrists, other physicians, and researchers.
Clinical Trials in Optic Nerve Disease Treatment is a valuable resource for ophthalmologists, optometrists, other physicians, and researchers.
Caracteristici
Offers a comprehensive review of clinical trials in Optic Nerve Disease Treatment The first book to provide coverage on clinical trials in Optic Nerve Disease Treatment Covers active studies as well as completed, withdrawn, and terminated studies